Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report

BackgroundCDK4/6 inhibitors (CDKi), namely, palbociclib, ribociclib, and abemaciclib, combined with either an aromatase inhibitor (AI) or fulvestrant are the standard first/second line for hormone receptor-positive(HR+)/HER2-negative(neg) metastatic breast cancer (MBC). However, the choice of one sp...

Full description

Bibliographic Details
Main Authors: Francesco Schettini, Elia Seguí, Benedetta Conte, Esther Sanfeliu, Blanca Gonzalez-Farre, Pedro Jares, Sergi Vidal-Sicart, Sergi Ganau, Isaac Cebrecos, Fara Brasó-Maristany, Montserrat Muñoz, Aleix Prat, Maria Vidal
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
intrinsic subtype
HER2-enriched
ribociclib
metastatic breast cancer
hormone receptor (HR)
HER2-negative
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1009352/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1009352/full

Similar Items